Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jan 12:7:7.
doi: 10.1186/1471-2407-7-7.

Lymphatic vessels assessment in feline mammary tumours

Affiliations

Lymphatic vessels assessment in feline mammary tumours

Giuseppe Sarli et al. BMC Cancer. .

Abstract

Background: The lymphatic vessels play a crucial role in a variety of human cancers since tumour cell lymphatic invasion significantly influences prognosis. It is not known if pre-existing lymphatics are enough for tumour dissemination or de novo development is necessary. VEGFR-3 is an angiogenetic mediator for both lymphatic and blood vessels during embryonic development, and only for lymphatics after birth. VEGF is a mediator of both vasculogenesis and angiogenesis, regulates the growth of lymphatics in various experimental models, and is produced in many solid tumours. CD44 mediates hyaluronic acid (HA)-dependent cell adhesion: besides promoting invasion, this interaction also supports neoangiogenesis that indirectly stimulates tumour cell proliferation. The expression of VEGF-C (Vascular Endothelial Growth Factor-C), its receptor VEGFR-3 and CD44, were studied on feline mammary samples to assess the importance of lymphangiogenesis and lymphangiotrophism in neoplasia.

Methods: Samples were taken from six normal mammary glands (NMG), ten benign (BT) and 32 malignant (MT) tumours. Immunohistochemical laminin/VEGFR-3 double stain, VEGF-C and CD44 stains were applied to 4 mum-thick sections, and their expression evaluated in intratumoral/extratumoral and intramammary/extramammary fields.

Results: All groups revealed a higher number of lymphatics in the extratumoral/extramammary areas. VEGF-C expression in the epithelium paralleled the number of positive vessels in the NMG, BT and MT, whereas VEGF-C higher expression was noted in the intratumoral fields only in infiltrating MT. CD44 score was lower in extratumoral than intratumoral fields in tumours and showed a significant increase in extramammary/extratumoral fields from NMG to MT. Pearson test showed a significant and inversely proportional correlation between CD44 expression and the number of lymphatic vessels with VEGFR-3 in malignant infiltrating tumours.

Conclusion: The number of both VEGFR-3 positive and negative lymphatics in the extratumoral and extramammary stroma was significantly higher than intratumoral and intramammary fields respectively in the NMG, BT and MT. This suggests a scant biological importance of intratumoral lymphatics while their higher number is due to the concentration of existing vessels following compression of the extratumoral stroma in spite of a non demonstrable increase from NMG to MT. The tumour model employed provided no evidence of lymphangiogenesis, and metastasis in the regional lymph node develops following the spread through the pre-existing lymphatic network.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cat. Mammary gland. VEGFR-3 (red) and laminin (brown) double immunohistochemical stain in an extratumoral area of a stage 0 carcinoma. Lymphatic vessels are laminin negative (asterisk) whereas blood vessels are laminin positive (circle) 20X. Inset: higher magnification of VEGFR-3 positive endothelial cells in a lymphatic vessel. 63X.
Figure 2
Figure 2
Number of lymphatics with and without VEGFR-3 expression in intramammary/intratumoral (A, B) and extramammary/extratumoral (C, D) fields in normal mammary gland (NMG), benign tumours (BT) and malignant tumours (MT).
Figure 3
Figure 3
Number of lymphatics with and without VEGFR-3 expression in intratumoral (A, B) and extratumoral (C, D) fields in stage 0, stage I and stage II malignant tumours.
Figure 4
Figure 4
Cat. Mammary gland. Strong cytoplasmic and light nuclear VEGF-C positivity in cells of solid carcinoma. 40X.
Figure 5
Figure 5
VEGF-C score index in normal mammary gland (A), benign tumours (B), non-invasive (C) and invasive malignant (D) tumours.
Figure 6
Figure 6
Cat. Mammary gland. CD44 cytoplasmic positivity of carcinoma infiltrating cells close to a lymph vessel. 40X.
Figure 7
Figure 7
CD44 score index in extramammary/extratumoral fields of NMG, BT and MT.

Similar articles

Cited by

References

    1. Schoppmann SF, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C, Kriehuber E, Nagy K, Alitalo K, Kerjaschki D. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. American Journal of Pathology. 2002;161:947–956. - PMC - PubMed
    1. Pepper MS. Lymphangiogenesis and tumor metastasis: myth or realty? Clinical Cancer Research. 2001;7:462–468. - PubMed
    1. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell. 1999;98:769–778. doi: 10.1016/S0092-8674(00)81511-1. - DOI - PubMed
    1. Breitender-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. American Journal of Pathology. 1999;154:385–394. - PMC - PubMed
    1. Jackson DG, Prevo R, Clasper S, Banerji S. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends in Immunology. 2001;22:317–321. doi: 10.1016/S1471-4906(01)01936-6. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources